In the early 1980s it was discovered that a unique pentasaccharide domain in some heparin chains activates antithrombin III (AT-III), a serine protease inhibitor that blocks thrombin and factor Xa in the coagulation cascade. Sanofi-Synthlabo and Organon developed a synthetic analogue of this ...
The way in which low-molecular-weight heparins work is by their action on anti-Xa factor. Blood clotting involves a complex cascade of enzymes and actions. They increase the antithrombin III-mediated inhibition of the formation and activity of factor Xa, a key player in clot formation. In so...
Neuraxial anesthetic techniques are commonly used during the peripartum period to provide effective pain relief for labor and anesthesia during cesarean delivery. Major neurologic complications are rare after neuraxial anesthesia; however, spinal hematoma is associated with catastrophic neurologic outcomes (inc...
Prothrombin fragment 1–2 and thrombin–antithrombin (TAT) complexes appear in the circulation when thrombin is being generated in the body. Increased in-vivo TG indicates an on-going pathologic process14; whereas elevated or decreased ex-vivo TG implies that the function of the coagulation process...
clotting in the bubble trap and the dialyzer concluded that ISF does not alleviate coagulation, but rather promotes clot formation.7 This study suggested that saline flushes may lead to momentary ECC dilution of the anti-coagulation Factor Xa activity, which may contribute to increased coagulation. ...
Although the exploration of antithrombotic agents that act on well-established targets such factor Xa and thrombin remains the mainstay, attention has also shifted to other factors in the coagulation cascade. The evidence emerging from clinical research is growing, generating exciting possibilities in ...
Methods with potential utility for quantitative assessment of DOACs include plasma drug concentrations, ecarin clotting time, dilute thrombin time, and anti-factor Xa concentrations. Noncoagulation laboratory monitoring should include serum creatinine, liver function tests, and complete blood counts. Clinical...
In the early 1980s it was discovered that a unique pentasaccharide domain in some heparin chains activates antithrombin III (AT-III), a serine protease inhibitor that blocks thrombin and factor Xa in the coagulation cascade. Sanofi-Synth茅labo and Organon developed a synthetic analogue of this ...
In the early 1980s it was discovered that a unique pentasaccharide domain in some heparin chains activates antithrombin III (AT‐III), a serine protease inhibitor that blocks thrombin and factor Xa in the coagulation cascade. Sanofi‐Synthélabo and Organon developed a synthetic analogue of this ...
Although the exploration of antithrombotic agents that act on well-established targets such factor Xa and thrombin remains the mainstay, attention has also shifted to other factors in the coagulation cascade. The evidence emerging from clinical research is growing, generating exciting possibilities in ...